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INTRODUCTION 
 Upper Gastrointestinal (UGI) bleeding is a common clinical problem 
with an incidence of 103-172 / 1,00,000 persons per year1,2. Forty four percent 
of hospitalisations for upper GI bleeding are for patients older than 60 yrs of 
age3. Approximately 80% upper GI bleeding are self limited and require only 
supportive therapy4. Patients with continued or recurrent bleeding have 
mortality rates of 25% to 30%4. 
Definition 
 By definition UGI bleed is bleeding from the GI tract proximal to the 
`ligament of Treitz'. 
Gastrointestinal bleeding encompasses a broad array of clinical 
scenarios. The spectrum is diverse because of the multiple types of lesions that 
can cause bleeding, and because bleeding can occur from virtually any where 
in the gastrointestinal tract. Additionally, gastrointestinal bleeding varies 
greatly in its volume and as such may be massive or trivial, and may be 
clinically apparent or altogether hidden. Gastrointestinal bleeding is manifest in 
one or more of the following clinical scenarios (1) bleeding is from the upper 
gastrointestinal tract; (2) bleeding is from the lower gastrointestinal tract; (3) 
bleeding is occult (ie, unknown to the patient); or (4) bleeding is clinically 
obvious but the site (ie, whether it is from the upper or lower gastrointestinal 
tract) is obscure. Patients with occult bleeding are challenging because the 
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patient is unaware of the bleeding and clinical clues to its cause are typically 
lacking. Patients with obscure bleeding are particularly challenging because 
their bleeding is typically recurrent and the site of bleeding is difficult 
accurately to identify. 
 Bleeding from the upper gastrointestinal tract is approximately five 
times more common than from the lower gastrointestinal tract5 and seems to be 
more common in men and the elderly6. 
The clinical presentation of patients with gastrointestinal bleeding 
typically reflects the site, etiology, and rate of bleeding. Gastrointestinal tract 
bleeding is manifest in one or more ways. Hematemesis, melena, or 
hematochezia are the most common manifestations of gastrointestinal bleeding. 
Hematemesis is defined as vomiting of blood and is caused by upper 
gastrointestinal bleeding from the esophagus, stomach, or proximal small 
bowel. Blood may be bright red or it may be old and take on the appearance of 
coffee grounds. Melena is defined as passage of black, tarry, and foul-smelling 
stools. The black, tarry character of melena is caused by degradation of blood 
in the more proximal colon ( and is typical of bleeding from the upper 
gastrointestinal tract). Melena should not be confused with the greenish 
character of ingested iron or the black, non-foul-smelling stool caused by 
ingestion of  bismuth (ie, in compounds, such as bismuth subsalicylate). 
Hematochezia refers to bright red blood from the rectum that may or may not 
be mixed with stool. Occult gastrointestinal bleeding denotes bleeding that is 
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not apparent to the patient and is caused by small amounts of bleeding. Obscure 
gastrointestinal bleeding refers to obvious (eg, manifest by hematemesis, 
melena, or hematochezia) bleeding, but from a source that is not easily 
identified on routine examination. 
The epidemiology of UGI bleed has changed in the last 15 years. Recent 
development in the diagnosis and treatment of UGI bleed have been offset by 
the wide spread use of NSAIDS which increase the risk of Acute UGI bleed by 
almost 4 times overall in the general population. The net effect of these 
contrasting forces have caused large swings in the origin of UGI bleed. 
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AIM OF THE STUDY 
1. To analyse various parameters that carry higher risk in patients 
with UGI bleed. 
2. To develop a clinical scoring to identify patients with high risk 
UGI bleed (HRB).  
3. To find out the correlation of our clinical scoring with endoscopic 
findings. 
4. To determine the sensitivity of clinical scoring in identifying 
patients with high risk. 
5. To assess the short term outcome (Rebleeding & Mortality) in 
those patients who had UGI bleed. 
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REVIEW OF LITERATURE 
Aetiology of Upper Gastrointestinal Bleed 
1. Duodenal Ulcer 
2. Gastric Ulcer 
3. Esophageal Varices 
4. Esophagitis 
5. Mallory-Weiss Tear7,8 
6. Erosive Gastritis due to 
  a) Alcohol9 
b) Non-Steroidal Antiinflammatory Drugs (NSAIDS), 
Aspirin, Steroids, Antimetabolites likie 5-FU, Caffeine. 
c) Chemicals - Kerosene, Ammonia, Acetone, Terpentine, 
Arsenic, Bromides, Copper Sulphate, Corrosive acids. 
d) Stress Ulcers - Due to Burns, Trauma, Prolonged medical 
illness, Post-operative complications. 
 e) Thermal Injury 
  f) Gastric Irradiation 
 g) Infections 
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7. Neoplasms - Carcinoma Esophagus, Gastric Carcinoma, 
Leiomyoma, Haemangioma, Melanoma, Lymphoma, Polyps  
8. Aorto-Enteric Fistula10,11 
9. Vascular Anamolies - Rendu-Osler Weber syndrome12, CREST 
syndrome, Angiodysplasias13 
10. Haematological disorders - Leukaemia, Thrombocytopenia, 
Haemophilia, DIC, Polycythemia vera, Von-Willebrands disease. 
11. Vasculitis - Pan arteritis nodosa, Henoch  Schonlein purpura. 
12. Occult UGI Bleed 
Esophagus - Cameron erosions 
Stomach - Portal hypertensive gastropathy, 
     Dieulafoy's disease14, 
     GAVE - Watermelon stomach, 
    AVM - Angiodysplasia 
Biliary Tree  - Haemobilia (trauma or calculus) 
Pancreas  - Aneurysm (Haemosuccus Pancreaticus) 
Small Intestine - Portal hypertensive intestinal vasculopathy, 
Neoplasias (leiomyoma, leiomyosarcoma 
adenocarcinoma), Arteriovenous 
malformation (angiodysplasia), Aortoenteric 
fistulas. 
Drug induced mucosal lesions (NSAIDS) 
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Of all the causes listed, the common causes are the following,  
1. Peptic Ulcer Disease 
2. Erosive Gastritis 
3. Variceal Bleed 
4. Mallory-Weiss Tear 
Peptic Ulcer Disease -  Peptic Ulcers are mucosal defects in the 
duodenum or stomach caused by a breakdown in the normal mucosal defences. 
It accounts for approximately 45% of UGI Bleed. Duodenal ulcer accounts for 
25% and Gastric Ulcer for 20% of the bleed. NSAIDS and alcohol have been 
implicated as contributing factors alongwith excess of stomach acids. H.Pylori 
is another major contributing factor and there has been a formidable amount of 
interest and research in this organism and its clinical effects15. It is now known 
that nearly 100% of chronic superficial gastritis, 90% of Duodenal ulcer and 
80% of Gastric ulcer are caused by H.Pylori. Multiple studies show that 
eradication of the organism markedly decreases the rate of ulcer recurrence. 
Stress induced ulcer caused due to Head injury are Cushing's ulcers and 
that due to Burns are Curling's ulcers. 
Erosive Gastritis -  Bleeding assocaited with this comes from diffuse 
superficial erosions in the gastric mucosa which are usually caused by local 
irritants such as NSAIDS, alcohol, or due to stress. Approximately 20% of UGI 
Bleed is caused by this. 
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NSAIDS decrease the synthesis of protective prostaglandins by 
inhibiting cyclo-oxygenase and may have direct effects on the gastric mucosa 
causing irritation and superficial lesions16. Alcohol ingestion is a frequent cause 
of gastropathy. The gastric mucosa produces leukotrienes when exposed to 
alcohol and these may be responsible for the vascular stasis, engorgement and 
increased vascular permeability which leads to  haemorrhage. 
Major physiologic stressors like, burns, sepsis, trauma are often 
associated with gastritis. Decreased splanchnic blood flow during times of 
severe stress may cause a decrease in the mucus production, bicarbonate 
secretion and prostaglandin synthesis leading to breakdown in the normal 
mucosal defence. 
Variceal Bleed -  Varices are spontaneous venous dilatations of porto 
systemic collaterals that develop from portal hypertension. Approximately 10% 
of UGI Bleed is caused by this.1/3rd of patients with cirrhosis will bleed from 
varices17. Child Class C cirrhotics have 50% mortality rate for the first 
haemorrhage. Death is frequently not directly caused by variceal haemorrhage, 
but by other end organ failure such as aspiration, hepatic failure, sepsis or renal 
failure. Varices develop when there is a hepatic vein pressure gradient of more 
than 12 mm of Hg18. This is an indirect way of measuring portal vein pressure. 
Bleeding is most likely to develop when the Hepatic vein pressure gradient is 
greater than 18mm of Hg. Prediction of bleeding is difficult and influenced by 
the size and thickness of the varices. Esophageal varices are the most common 
venous collaterals but many other porto systemic collaterals can exist and are 
difficult to treat. Most gastric varices are associated with esophageal varices 
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and surgical intervention is frequently required. Hence the use of TIPS is 
becoming more common now19. 
Mallory-Weiss Tear - This occurs at the distal esophagus at the 
Gastroesophageal junction presumably after retching or vomiting although 
there is a lack of this antecedent history. This accounts for 7% of UGI Bleed. 
Bleeding occurs when the tear involves the underlying Esophageal venous or 
arterial plexus. It appears as an elliptic ulcer at the Gastroesophageal junction 
within a  Hiatal hernia or in the gastric side just below the Gastroesophageal 
junction endoscopically. The majority heal within 24-48 hours. But patients 
with Portal hypertension are at an increased risk of massive bleeding from this 
compared to Non-Portal Hypertension patients. Endoscopic therapy is reserved 
for tears with active bleeding. Contiguous varices can be treated with 
sclerotherapy, band ligation or combination therapy. Angiography can be 
performed to embolise a bleeding vessel. 
APPROACH TO THE PATIENTS WITH UGI BLEED  
INITIAL PATIENT ASSESSMENT 
 When a patient is found to have one of the previously mentioned 
manifestations of gastrointestinal bleeding the first step in management should 
be to assess the severity of bleeding. Assessment of the patient's hemodynamics 
should be emphasized (Table 1 ). This hemodynamic assessment forms the 
basis for further management. Ongoing assessment of the vital signs further 
focuses resuscitation efforts, and also provides important prognostic 
information. Finally, ongoing and careful assessment of the patient's 
hemodynamic status helps triage appropriate intervention. For example, 
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patients with obviously unstable vital signs are often bleeding from  major 
vascular sources, such as an ulcer with a visible vessel or gastroesophageal 
varices20; the prognosis of these patients is poorer than that of those with 
normal vital signs. and their clinical condition mandates more aggressive and 
timely intervention than patients with normal vital signs. 
RESUSCITATION 
 The more severe the bleeding (ie, unstable vital signs and evidence of 
ongoing bleeding), the more vigorous the resuscitation efforts should be. In 
patients who have any evidence of hemodynamic instability, two large -bore 
intravenous catheters should be placed immediately. Colloid (normal saline or 
lactated Ringer's solution) should be infused as rapidly as the patient's 
cardiovascular system allows to restore the vital signs towards normal. ICU 
monitoring is indicated in hemodynamically unstable patients. Supplemental 
oxygen by nasal cannula or facemask should be given liberally. Vital signs and 
urine output should be monitored closely, and in selected situations (for 
patients with underlying cardiopulmonary disease) central venous monitoring is 
helpful. The importance of aggressive ICU monitoring and resuscitation has 
been emphasized by investigation suggesting that it may decrease mortality21. 
 In addition to colloidal solution, patients must typically undergo blood 
transfusion. Decision about when and how much to transfuse the patients with 
gastrointestinal bleeding is often complicated and requires integrations of 
multiple aspects of the clinical situation. Virtually all patients with unstable 
vital signs have had significant blood loss and  require blood transfusion. If the 
patient has subnormal tissue oxygenation, transfusion should be aggressive. 
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Patients with continued instability in vital signs, continued bleeding, symptoms 
of poor tissue oxygenation, or persistently low hematocrit value (20% - 25%) 
likewise should probably be transfused continuously. It is most appropriate to 
raise the hematocrit to a level of 30% in elderly patients, whereas in younger, 
otherwise healthy patients, hematocrit values in the 20% to 25% range may be 
satisfactory; in those with portal hypertension, it should not be above 27% to 
28%. Transfusion should be with packed red blood cells, except in rare 
circumstances where whole blood transfusion  may be used in those who 
cannot be cross-matched in a timely fashion. In those with specific defects in 
coagulation factors or platelets, these substances can be replaced. Patients 
requiring greater than 10 units of packed red blood cells should receive Fresh-
frozen plasma or platelets or both. Warmed blood should be administered to 
patients requiring massive transfusion. (ie, > 3000 m L). The hematocrit should 
be monitored serially (typically after a specific transfusion). Serial hematocrits 
are not a substitute, however, for ongoing clinical assessment of the 
hemodynamics. Frequently, patients with chronic bleeding may have a low 
hematocrit, but no evidence of hemodynamic instability. In this situation, blood 
transfusion should be slow and deliberate, regardless of the hematocrit value. 
TABLE  - 1 
 
HEMODYNAMICS, VITAL SIGNS, AND BLOOD LOSS 
 
Hemodynamics  
vital sign 
% Blood loss (fraction of 
intravascular volume) 
Bleed type 
Shock (resting hypotension ) 20-25 Massive 
Postural (orthostatic tachycardia 
or hypotension) 
10-20 Moderate 
Normal <10 Minor 
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HISTORY, SYMPTOMS, AND SIGNS 
 Once the patient's hemodynamics and overall condition has been 
assessed and stabilized, attention should turn to the clinical history. The history 
helps the clinician assess the severity of bleeding and make a preliminary 
assessment of the site and cause. Historical features important in assessing the 
etiology of gastrointestinal bleeding are shown in Box 1. 
Box 1 : Historical features in the assessment of gastrointestinal bleeding 
Age 
Prior bleeding 
Previous gastrointestinal disease 
Previous surgery 
Underlying medical disorder (especially liver disease) 
Nonsteroidal anti-inflammatory drugs (NSAIDs), Aspirin (ASA) 
Abdominal pain 
Change in bowel habits 
Weight loss or anorexia 
History of oropharyngeal disease 
 
 Simple demographic charecteristics are an essential part of the history. 
For example, elderly patients may bleed from a number of diseases less 
common in younger persons (ie, vascular ectasia, diverticula, ischemic colitis, 
cancer), whereas bleeding in younger patients is more likely to be from 
esophagitis, varices, or Meckel's diverticula (typically lower gastrointestinal 
bleeding in patients under 30 years of age). A past history of previous 
gastrointestinal disease or previous bleeding should focus the differential 
diagnosis immediately on related bleeding (eg, hereditary hemorrhagic  
telangiectasia, ulcer disease, diverticular bleeding). A history of previous 
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surgery is likewise important. For example, a history of previous aortic surgery 
should increase the suspicion for aortoenteric fistula. A history of liver disease 
raise the possibility of bleeding associated with portal hypertension. Ingestion 
of medications, such as aspirin or other nonsteroidal anti-inflammatory drugs, 
makes bleeding from ulceration more likely. Patients taking anticoagulant 
medications may be more likely to bleed from ulcers or vascular ectasias. 
Gastrointestinal bleeding in the setting of anticoagulation therapy, even in 
patients taking warfarin and who have a supratherapeutic international 
normalized ratio, is most often caused by underlying gastrointestinal tract 
pathology and should not be ascribed to over anticoagulation22. Other important 
historical features include abdominal pain (which suggests peptic ulcer disease, 
mesenteric or colonic ischemia) retching (Mallory - Weiss tear); or change in 
bowel habits, anorexia, or weight loss, all of which point to malignancy. 
Interestingly, elderly patients may be less likely to report abdominal pain 
associated with bleeding ulcers23. The history is also critical in ascertaining 
whether nongastrointestinal sources may be the casue of reported or witnessed 
bleeding, especially from the lungs or nasopharynx. 
 Physical examination should focus on putative evidence of liver disease 
(splenomegaly, ascites, caput), which increases the likelihood of portal 
hypertension and related cause of bleeding. The skin may also reveal evidence 
of chronic liver disease (eg, cutaneous spider angiomata, Dupuytren's 
contractures). Acanthosis nigricans may reflect underlying cancer (especially 
gastric cancer). Cutaneous telangiectases of skin or mucous membranes and 
lips raise the possibility of hereditary hemorrhagic telangiectasia (Osler - 
Weber - Rendu disease); pigmented lip lesions are seen with Peutz - Jeghers 
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syndrome; cutaneous tumors suggest neurofibromatosis; and purpura is 
consistent with vascular disease (Henoch - Schonlein purpura or polyarteritis 
nodosa). Abdominal tenderness (peptic ulcer, pancreatitis, and ischemia), 
abdominal masses, lymphadenopathy (malignancy), and splenomegaly 
(cirrhosis, splenic vein thrombosis) are all important to detect. 
 Hematemesis, melena, and hematochezia are classic symptoms and 
signs of gastrointestinal bleeding. It requires at least 50 mL of blood in the 
upper gastrointestinal tract for melena to become clinically apparent, although 
volumes of up to 100 mL of blood when infused into the stomach may be 
clinically silent24. When bright red blood is vomited, this typically signifies 
upper gastrointestinal bleeding that is significant, and is often caused by varices 
or an arterial lesion. Smaller amounts of bleeding that is significant, and is 
often caused by varices or an arterial lesion. Smaller amounts of bleeding from 
many other lesions are alarming to patients, however, and are often reported. 
Careful inquiry about the volume of vomited blood is essential. Witness of the 
amount of  and character of blood may also be useful in ascertaining the 
character of bleeding. Patients with coffee ground emesis are not usually 
bleeding actively but have had a recent or even remote bleed. Although 
hematochezia can be caused by bleeding from many different sites in the 
gastrointestinal tract, the higher the site of bleeding the more hemodynamically 
significant. Small amounts of hematochezia are often reported by the patient, 
and care should be taken to ascertain the volume of blood. Chronic occult 
blood loss may lead to end-organ symptoms, such as lightheadedness, dyspnea, 
angina pectoris, or even myocardial infarction. 
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 Bedside examination of the character of the stool is an essential and 
mandatory part of the physical examination. This part of the examination 
provides critical information about the site of bleeding, and also about the 
acuity of bleeding. For example, patients who are passing stools containing red 
blood, maroon-colored blood, or melena have active bleeding. In contrast, 
patients with brown stools are unlikely to have aggressive bleeding. Likewise, 
patients with infrequent stools are unlikely to have active bleeding, and those 
with a history of coffee ground emesis only and normal appearing stools, 
whether positive for occult blood or not, have usually had a trivial bleed. 
DIAGNOSIS 
Endoscopy 
 This has become accepted as the diagnostic study of choice in UGI 
Bleed25. It is well known that the majority of UGI Bleed will stop 
spontaneously and it is unlikely that urgent endoscopy will improve care or 
survival. However, 20% of the patients will have continued bleeding or have 
high risk lesions that will benefit from endoscopic evaluation and therapy. 
 Major therapeutic decisions will also be made based on endoscopic 
findings in patients with portal hypertension, prior gastric surgery and 
suspected aorta enteric fistula. Sclerotherapy of varices, treatment of actively 
bleeding lesions and treatment of high risk lesions in ulcers have been shown to 
improve survival, lower transfusion requirements, and decrease morbidity. 
Endoscopy may be most helpful in determining which of the several potential 
lesions are actually bleeding and in predicting which patients may rebleed as 
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evidenced  by a visible vessel in an ulcer crater. Diagnostic accuracy is highest 
if performed within first 24 hours of bleeding26. 
Hazards of Endoscopy 
1. Erroneous Diagnosis-With an experienced person errors are minimal. 
2. Complications of Medication 
a) Local anaesthesia 
i.   Acute cardiac rhythm disturbance 
ii. Circulatory failure 
b) Diazepam 
 i. Increased salivation 
 ii. Tendency to pulmonary aspiration 
 iii. Amnesia 
3. Perforation 
4. Pulmonary aspiration 
5. Cardiovascular complications 
9 Changes in cardiac rhythm 
9 Supra ventricular ectopics 
9 Ventricular ectopics 
9 ST-T changes 
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The morbidity and mortality in endoscopy is very low (0.3% to 0.03% 
respectively). 
Endoscopic therapy 
 The choice of modality is generally not important. Institutional 
preference, the experience of the endoscopist and the availability of resources 
are the most important determining factors. For treatment of bleeding ulcers, 
laser therapy is useful but less effective than the other modalities, but due to 
high cost, immobility, and other technical reasons, laser therapy is not used for 
UGI Bleed. 
 Active haemorrhage can be controlled using heater probe. The heater 
probe delivers energy as heat to the distal, coated tip. Haemostasis is achieved 
by the use of direct pressure to the bleeding site with heat. 
 Injected substances include 1% polidocanol, thrombin, Absolute 
ethanol, epinephrine (1:10,000 dilution), and sodium tetradecyl sulfate. 
Injection therapy was atleast as effective as thermal therapy at preventing 
surgery and decreasing mortality in patients with bleeding ulcers. 
 Endoscopic Sclerotherapy (EST) has become widely available in the last 
two decades and is now the most common definitive therapy for bleeding 
esophageal varices27. Multiple agents have been used including sodium 
tetradecyl sulfate (1% to 3% solution), ethanolamine 5% and polidocanol. The 
type of sclerosant used does not appear to be important and intravariceal 
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injection is preferred to paravariceal injection, but both methods are effective. 
For acute control of haemorrhages, EST has 66-100% success rate and has 
proved more effective than balloon tamponade or medical therapy. 
 In 1986 Van Stiegmann and associates reported a new technique for 
endoscopic therapy of varices. It involved the placement of a small rubber band 
over the varices and has been termed Esophageal Band Ligation (EBL). EBL 
showed a significantly lower complication rate than EST (2% vs 22%) 
including less mortality28. Acceptance of EBL has been limited for several 
reasons. Multiple bandings per session are required and the present devices can 
only place one band before requiring reloading. Due to frequent removal of the 
scope for reloading, an overtube is required. The  overtube may be difficult to 
place and many gastroenterologists are not trained to perform the procedure. 
Clear distal sleeves (which will make visualization of the varices easier), 
multiple banding devices are under development and may facilitate acceptance 
of this new technique and more widespread use. 
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THERAPY OF SPECIFIC LESIONS WITH 
UGI BLEED 
 
 The following algorithms are followed for management of suspected 
non - variceal and variceal UGI Bleed in general. 
 
Fig. 1 
 
I. Treatment algorithm for suspected nonvariceal upper 
gastrointestinal bleeding 
 
 
 (+) Nasogastric tube (-)
Aspirate
Black Red (-) Hct > 30, VSS (+)
Ward and
elective EGD
ICU, GI
consultation, and
urgent EGD
(+)
Hct > 30,
VSS (-)
Ward and
elective EGD
Bleeding
controlled
No Yes
Obtain surgical
consultation and
angiography
Observe and
administer H2
blocker
EGD - Esophagogastro -
duodenoscopy
ICU - Intensive care unit
VSS - Vital signs stable
Hct  - Haematocrit
 
 
 
20
Fig. 2 
 
II. Treatment algorithm for suspected variceal bleeding 
 
 
(-)          Massive bleeding           (+) 
Somatostatin 
250 µg bolus 
then 250 µg/hr
or Vasopressin 
20 u/20 min 
then  
0.2 - 0.6 u/min 
plus 
NTG drip 40-
400 µg/min 
EGD EGD
Varices (+) Varices (-) 
UGI Bleed 
algorithm  
(Refer - I) 
UGI Bleed 
algorithm  
(Refer - I) 
(-) Sclerotherapy 
(+)  Bleeding (-) 
Ballon tamponade 
Propranolol 20-180 
mg PO bid (lower 
HR by 25%) 
(+)  Bleeding (-) 
Shunts and  
surgery 
EGD - Esophagogastro - duodenoscopy  
NTG - Nitroglycerin 
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 Peptic Ulcer disease: The goals of Ulcer therapy include relief of 
symptoms and prevention of recurrence and complication. 
a) Gastric Ulcer: In patients with Gastric Ulcer follow up with an upper 
endoscopy should be pursued until complete healing is documented. 
Surgical therapy should be considered for non-healing gastric ulcers as 
5% turn out to be malignant. 
b) Duodenal Ulcer: They are never malignant. Therefore, demonstration 
of ulcer healing in the absence of symptoms is unnecessary. 
c) H-pylori: This can be cultured from the stomach of approximately 90% 
of Duodenal Ulcer patients and 70% of Gastric Ulcer patients. 
Determination of Duodenal Ulcer or Gastric Ulcer by endoscopy should 
be followed by confirmation of H-Pylori infection. Ulcer patients with 
H-pylori infections require anti-microbial therapy. 
Reduction of stomach acidity and treatment of H-Pylori infection are the 
main goals of therapy in Peptic Ulcer Disease. 
I. Medical Treatment 
1) H-Pylori regimens: Triple therapy with the following combinations. 
 Bismuth subsalicylate, Metronidazole, Tetracycline (or) 
 Lansoprazole, Clarithromycin, Amoxicillin (or) 
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 Metronidazole, Amoxicillin, Omeprazole are used in appropriate dosage 
for about 2 weeks for eradication of H-pylori infection. 
2) H2-Receptor antagonists 
a) Duodenal Ulcer 
 Acute Therapy - Cimetidine, Ranitidine, Famotidine, Nizatidine, 
Roxatidine are all effective. 
 Prevention Therapy - Therapy to prevent recurrent ulcer disease 
includes eradication of H-pylori infection and maintenance of H2 
receptor antagonist therapy. There is no consensus on length of 
treatment. 
 Benign Gastric Ulcer-Cimetidine, Ranitidine and Famotidine are all 
effective in dealing gastric ulcer. 
 Proton Pump inhibitors-Omeprazole, Lanzoprazole profoundly 
decrease gastric acid secretion by inhibiting Hydrogen-potassium 
adenosine triphospates. 
 Sucralfate - As effective as H2 receptor antagonist or high dose 
antacids in healing Duodenal Ulcer. It acts locally on the mucosal 
surface. 
 Antacids - Used best as supplemental therapy for pain relief. Choice 
is determined by buffering capacity, sodium content and side effects. 
In general liquid antacids are more effective than tablets. 
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6) Other therapeutic measures 
¾ Dietary modification - Avoidance of food that are reproducibly 
associated with dyspeptic symptoms. However, there is no evidence 
that a bland diet, improves symptoms or promotes ulcer healing. 
¾ Cessation of smoking - Smoking is associated with an increased risk 
of peptic ulcer disease, delayed ulcer healing and an increased rate of 
recurrence29. 
¾ NSAIDS and Aspirin - These should be avoided as they are toxic to 
the gastric mucosa and are associated with dyspepsia and mucosal 
ulceration. Concomitant therapy with proton pump inhibitors, H2 
receptor antagonist or sucralfate may ameliorate these symptoms. 
Misoprostal can help prevent NSAIDS associated gastric ulcer30. 
¾ Alcohol - Should be avoided as it damages the gastric mucosal 
barrier and is associated with gastritis. 
II. Surgery 
Indications: 
Absolute  : Massive bleeding 
   Combined perforation and bleeding 
Relative  : Presence of persistent shock 
   Rebleeding after admission 
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   Obvious arterial bleeding at the time of endoscopy 
Demonstration of large chronic ulcers, continued slow 
bleeding 
III. Arterial angiotherapy  
Can be used to control massive UGI Bleed in patients considered at high 
risk for surgical interventions. 
1) Arterial Vasopressin produces cessation of bleeding in some 
gastric lesions and duodenal ulcer. But patients with known 
cardiac disease are at increased risk for complications of 
vasopressin. 
2) Arterial embolization with absorbable gelatin sponge (Gelfoam). 
By this, control of bleeding is obtained in 70% of patients. 
Specific treatable lesions include 
¾ Mallory Weiss tear (100%) 
¾ Duodenal Ulcer and bleeding gastritis (67%) 
¾ Gastric ulcer (50%) 
¾ Stress ulcer (55%) 
Other agents used for arterial embolization include cyanoacrylate and 
thrombin. 
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3) Intravenous Vasopressin-The IV route is not recommended in 
bleeding lesions other than esophageal varices because 
vasopressin is ineffective in arterial bleeding and has no proven 
effect in other bleeding lesions. 
Esophageal Variceal Haemorrhage 
 This is a medical emergency associated with high morbidity and 
mortality. If the diagnosis is confirmed and active bleeding persists several 
therapeutic options exist. 
1) Endoscopic Therapy: Treatment of choice for acute variceal bleed. 
After the acute variceal haemorrhage has been controlled by endoscopic 
therapy it is also used to prevent variceal rebleeding. 
a) Sclerotherapy - Effective for controlling primary haemorrhage 
and obliterating varices after the initial bleeding episode but is 
associated with significant complications. Recurrent bleeding 
occurs in upto 50% of patients that can be controlled with further 
sclerotherapy. 
 Complications-Ulceration, strictures, perforation, sepsis, fever. 
b) Variceal ligation or banding - As effective as sclero therapy in 
controlling active haemorrhage and achieves variceal eradication 
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more rapidly with low rates of rebleeding and few 
complications31. 
Complications - Superficial ulceration, dysphagia, esophageal strictures, 
transient chest discomfort. 
2) Pharmacologic Therapy : Less effective than endoscopic therapy. 
Nevertheless ready availability, ease of administration and the potential 
for success makes it a reasonable alternative when other therapies are 
unavailable. 
a) Octreotide acetate - Long acting synthetic analogue of 
somatostatin. Given as 50-100 micro gram. IV bolus followed by 
an infusion of 25-50 micro gm/hour. 
b) Vasopressin - Until recently, was the most widely used agent. A 
standard mixture of 100 units of vasopressin in 250ml of D5W. 
Starting dose 3 units/minute IV for 30 minutes followed by 
increments of 3 units/minute every 30 minutes until haemostasis 
is achieved. Concomitant infusion of nitroglycerin may decrease 
the cardiovascular side effects of vasopressin and provide more 
effective control of bleeding32. 
3) Balloon tamponade - Effective in temporary control of variceal bleeding 
before more definitive therapy can be undertaken33. The Sengstaken-
Blakemore tube, Minnesota tube, Linton tube can be used. But this is 
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associated with a high rate of major complications and mortality from 
tube displacement. Endoscopy should confirm the site of bleeding and 
direct tube selection. 
4) Surgery - Portacaval or Distal spleno renal shunt34. This controls 
variceal bleeding in 95% of the patients. In patients with good hepatic 
reserve, shunts should be considered if the patient, 
¾ fails endoscopic or pharmacological therapy 
¾ unable to return for follow up 
¾ at high risk for death from recurrent bleeding 
5) Tips - Radiologic alternative to a surgical shunt. An expandable metal 
stent is placed between the hepatic veins and portal vein. TIPS 
effectively decompresses the portal vein and is used for the following 
patients.  
¾ one who fails endoscopic therapy 
¾ has gastric variceal bleeding 
¾ poor surgical candidates 
¾ awaiting liver transplantation 
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¾ recurrent variceal haemorrhage who fails to respond to 
endoscopic/pharmacological therapy35. 
6) Pharmacologic Prophylaxis - Beta adrenergic antagonist has shown to 
decrease Portal hypertension. Propranolol and Nadolol in dosages 
sufficient to decrease the resting heart rate by 25% are effective 
prophylactic therapy for first variceal bleeding in patients with large 
varices, and are effective in preventing recurrent variceal bleeding, 
though no benefit in overall survival has been shown36. The addition of 
oral nitrates, improves the therapeutic effect of beta adrenergic 
antagonist in preventing variceal haemorrhage and may be as effective 
as sclerotherapy. 
7) Hepatic Transplantation - In selected patients, this can reverse Portal 
hypertension and variceal haemorrhage. 
Mallory-Weiss tear - Most of them stop bleeding spontaneously and 
seldom have recurrent bleeding. Some require therapeutic endoscopic 
technique to control the bleeding. Selective infusion of vasopressin into the left 
gastric artery has been successful for patients who continue to bleed. Rarely 
surgery to oversew the bleeding vessel may be necessary. 
Erosive Gastritis - Identification of patients at risk allows for treatment 
to prevent ulcer formation and thus to prevent bleeding. At risk patients are 
those with 
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¾ major trauma 
¾ head injury 
¾ hypovolemic shock 
¾ sepsis 
¾ burns 
In medical ICU, significant UGI Bleed-frank blood or coffee grounds 
NG aspirate or melena occurs in 6% of patients and occult bleeding in 14%. 
Prophylactic therapy to prevent stress bleeding includes H2 antagonist, high 
potency antacids through NG tube. Patients with erosive gastritis due to alcohol 
or drugs are advised to abstain from alcohol and stop the offending drugs. They 
can be treated with H2 antagonists and antacids. 
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ENDOSCOPY 
 
 The flexible endoscopy is a complex tool. It consists basically of a 
control head with eye piece and controls, and flexible shaft which has a 
maneuverable tip. The head is connected to a light source via connecting 
"umbilical" cord through which pass other tubes transmitting air, water, and  
suction, etc. Accessories include flexible biopsy forceps for passage through 
the instrument, a side arm for assistant's viewing and cameras. The image is 
transmitted either by fibre optics or electronically from a video chip. 
 At the heart of any fibre optic instruments are the viewing and light 
carrying bundles. In most modern instruments the distal lens which focusses 
the image onto the bundle is fixed and transmitted to the eye via a focussing 
lens. 
 First generation video endoscopes are mechanically identical to fibre 
endoscopes with a video chip and supporting electronics mounted at the tip, to 
and fro wiring, replacing the optical bundle and further electronics and 
switches occupying the site of the optical lens on the upper part of the control 
head. The ease of stances, brighter view and the natural visual field makes 
video endoscopes exceedingly relaxing to use which is beneficial to good 
endoscopy and patient communication. 
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 The instruments used in our set up are 
1. Clympus CV-20 2. Pentax FG2QP 3. Pentax Video System 
 The whole apparatus consists of the following 
¾ The scope   
¾ Biopsy needles 
¾ Teaching scope 
¾ The light source 
¾ Brush 
¾ Video monitor 
 
 Procedure - Patients were advised nil oral from 8 pm the previous night 
until the commencement of the procedure the next day. Ryle's tube aspirtation 
was done in the morning one hour before the commencement of the procedure. 
Normally no medication is given to the patient. The patient was put on left 
lateral position, the scope smeared with xylocaine jelly and introduced under 
direct vision past the epiglottis into the esophagus. The patient was encouraged 
to swallow the tube and the mucosa was constantly visualised through the eye 
piece, at the same time keeping a watch over the distance traversed by the 
scope. At no time was undue force exerted to pass the instrument. 
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In the esophagus the mucosal pattern and presence of varices were 
looked for. The level of esophago-gastric junction and its patulence were 
observed. The tube was then passed into the stomach (by the J maneuver) and 
the body, antrum and fundus were visualised. The instrument was further 
passed into the duodenum and lesions if any were visualised. Then the scope 
was carefully withdrawn seeing the mucosal pattern once again to confirm the 
findings as well as to see if any traumatic lesions were produced by the 
instrument. During the entire procedure the patient's vitals were frequently 
monitored.   
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MATERIALS AND METHODS 
 50 consecutive patients admitted  in medical, surgical wards of 
Government General Hospital, Chennai, were taken into the study. 
Study design : Prospective study 
Venue  : Govt. General Hospital, Chennai. 
Study period : January 2006 to June 2006 
All patients were examined at the time of admission. Accurate history 
with emphasis on relevant past history, NSAIDS, past  UGI bleed, were taken 
in all patients. Complete physical examination was carried out as per protocol. 
Relevant  simple investigations were carried out in each patient within 2 hrs of 
admission. All the results were noted. 
All patients with UGI bleed were subjected to upper GI endoscopy 
within 24hrs. 
Endoscopy was done in Olympus CV-20 apparatus  by experienced 
Gastroenterologists and the findings were recorded. 
Endoscopic  interventions like injection therapy, Endoscopic sclero 
therapy, EVL were done as needed. 
The patients were treated with resuscitation, transfusion, 
vasoconstrictors, PPI, H2RI, antibiotics as needed. 
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All patients were observed for 1 week in hospital and evidence of 
rebleed, and death were recorded. All data were tabulated.   
Each parameter was assigned a  score, and patients with high risk were 
identified as   those with score > 20. 
Statistics 
 Statistical observations were done by Chi-Square chart with Pearson 
logistic regression analysis. 
 Based on quartiles the scores above 3rd quartile (75%) were called High 
risk and below 75% were called low risk. Patients above the score 20 (75%) 
were called high risk. 
 The values were recorded.  
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OBSERVATION 
 UGI bleed is a common medical emergency. As our hospital, the 
Government General Hospital, Chennai, being a tertiary care centre, we receive  
lot of cases of upper Gastrointestinal bleeding. we studied 50 cases of upper 
Gastrointestinal bleed, prospectively, and the observations are given below. 
AGE 
 The age of the patients admitted was from 15 - 75 years. We divided the 
patients into three age groups. The number of patients in each age group is 
given below. 
TABLE - 2 
 
AGE WISE DISTRIBUTION 
 
Age in years No. of Cases Total No. of Cases 
Percentage  
(%) 
< 40 21 50 42 
40 - 60 24 50 48 
> 60 5 50 10 
 
Predominant age group is  40 - 60 yrs, accounting for 48%. 
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GENDER 
 The incidence of UGI bleed in both Male and Female sex is as follows. 
 
TABLE - 3 
 
SEX  WISE DISTRIBUTION 
 
 
Sex No. of Cases Total No. of Cases Percentage 
(%) 
Male 40 50 80 
Female 10 50 20 
  
 Males were predominantly affected with UGI bleed. (80%). The ratio of 
Male : Female  is 4 : 1. 
MODE OF PRESENTATION 
 In our study, all the 50 patients, presented with Hemetemesis and none 
of them presented with melena alone. Of them, 45 patients presented with 
melena. Six patients had hematochezia. The mode of presentation is as follows. 
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TABLE - 4 
 
MODE OF PRESENTATION 
 
Presentation No. of Cases Total No. of Cases Percentage 
(%) 
Haematemesis 50 50 100 
H & Melena 45 50 90 
Haematochezia 6 50 12 
  
SEVERITY OF HAEMETEMESIS 
 One of the major determining factors of outcome is quantity of bleed. In 
our study 5 (10%) patients presented with massive haemetemesis. 
TABLE - 5 
 
SEVERITY OF HAEMETEMESIS 
 
Haemetemesis No. of Cases Total No. of Cases Percentage 
(%) 
< 500 ml 32 50 64 
500 - 1000 ml 13 50 26 
> 1000 ml 5 50 10 
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HAEMOGLOBIN 
 Haemoglobin percentage of the patients admitted with UGI Bleed, was 
calculated within 2 hrs of admission. We divided patients into 3 groups 
depending upon the severity of anemia. The results are given below. 
Hb% AT INITIAL PRESENTATION 
TABLE - 6 
 
Hb% AT INITIAL PRESENTATION 
 
Hb% (in grams%) No. of Cases Total No. of Cases 
Percentage 
(%) 
<5 5 50 10 
5 - 9 15 50 30 
≥ 10 30 50 60 
  
5(10%) patients presented with very severe anaemia with Hb% < 5 
gm%. 
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RYLE'S TUBE ASPIRATE 
 Ryle's tube aspirate was bright red in 15 (30%) patients, coffee - brown 
in 27 (54%) patients and was clear in 8(16%) patients. Bright red indicates 
current bleeding while coffee brown indicates recent or even old bleed. 
RECTAL EXAMINATION 
 Bright red colour noted in 5(10%) patients, maroon in 10 patients and 
black in 25 patients. Rectal examination was normal in the remaining patients. 
Bright Red Rectal examination is a high risk clinical feature indicating 
significant bleeding. 
VITAL PARAMETERS 
 Pulse, blood pressure and consciousness level play an important role in 
prognostication. The results are as follows. 
TABLE - 7 
 
VITALS 
 
Parameter Grade 
No. of 
patients 
Total no of 
cases 
Percentage 
(%) 
< 100 32 50 64 
100 - 120 10 50 20 Pulse 
> 120 8 50 16 
Blood pressure Normal 33 50 66 
 
40
Postural 
Hypotension 
11 50 22  
Resting 
Hypotension 
6 50 12 
Normal 30 50 60 
Dizziness 16 50 32 
Consciousness 
level 
Unconscious 4 50 8 
 
 Pulse > 120, Hypotension, unconsciousness are high risk features. 
HISTORY 
 * Of the 50 patients, 24 (48%) patients were alcoholics. 
 * 23 (46%) patients were smokers. 
* NSAIDS intake history was present in 9 (18%) cases, in the 
previous 48 hours. 
* Previous history of PUD was present in 10 (20%) cases. 
* Previous history of UGIB was present in 10 (20%) cases. 
COMORBIDITIES 
 Comorbidities are major determinants of adverse outcome in UGI bleed. 
* In our study, 7 patients had ascites. 
* Hepatic encephalopathy was present in 3 patients. 
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* Two patients had been admitted in intensive care unit. 
* Renal Failure was present for various reasons in 4 cases. 
 * Three patients had coronary artery disease. 
ENDOSCOPIC FINDINGS 
 After initial resuscitation and hemodynamic stabilisation, all the 50 
patients were subjected to upper Gastrointestinal endoscopy. The results are as 
follows : 
TABLE - 8 
 
ENDOSCOPIC FINDINGS 
 
Lesion No. of Cases Total No. of Cases Percentage 
(%) 
Peptic ulcer 23 50 46 
Gastric 4 50 8 
Duodenal 14 50 28 
Gastric + Duodenal 5 50 10 
Mallory weiss 6 50 12 
Erosions 10 50 20 
Ca stomach 2 50 4 
Variceal 9 50 18 
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TABLE - 9 
 
FORREST GRADING OF ULCER BLEED 
 
Lesion No. of Cases 
Total No. of 
Cases 
Percentage 
(%) 
Active bleeding 2 50 4 
NBVV 2 50 4 
Adherent clot 15 50 30 
Clean base  or 
pigmented ulcer 
22 50 44 
 
Peptic ulcer was the most common cause accounting for 46% of cases of 
UGIB. With duodenal ulcer, being the most frequent lesion (28%). High risk 
ulcers like, Ulcer with active bleeding and non bleeding visible vessel were 
diagnosed in 4 (8%) patients. 
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TABLE - 10 
 
VARICEAL FINDINGS 
 
Lesion No. of patients 
Mild 1 
Moderate 3 Grade 
Severe 5 
Mild 3 
Moderate 3 Column 
Severe 3 
Blue 5 
Colour 
White 4 
Present 5 
Gastric varices 
Absent 4 
Present 6 
PHT Gastropathy 
Absent 3 
Present 5 Red Colour signs 
(RCS) Absent 4 
 
 High grade varices, Red colour lesions, bluish varices are high risk 
features for Rebleed and mortality. 8 (16%) patients had high grade varices. 
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BLOOD TRANSFUSION 
 Of the 50 patients, 22 (44%) patients required blood transfusion and of  
them 9 (18%) patients required more number of blood transfusions. (>3 units). 
Blood transfusion was not required in 28 (56%) patients. High blood 
transfusion requirement is a high risk factor for adverse outcome. 
TABLE - 11 
 
BLOOD TRANSFUSION REQUIREMENT 
 
Blood transfusion No. of Patients Total no. of Patients 
Percentage 
(%) 
Total 22 50 44 
< 3 units 13 50 26 Required 
>3 units 9 50 18 
Not required 28 50 56 
 
ADVERSE OUTCOMES 
 After taking clinical and endoscopic scoring, we studied the clinical 
course of the patients. The results are as follows :- 
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TABLE - 12 
 
ADVERSE OUTCOME 
 
Outcome Rebleed 
Percentage 
(%) 
Death 
Percentage 
(%) 
Total No. of 
cases 
Non variceal 6 12 1 2 41 
Variceal 6 12 3 6 9 
Total 12 24 4 8 50 
 
 Rebleed was noted in 12 (24%) patients. 
Of the 41 cases of non - variceal bleed, 6 patients had rebleed (12%) and 
of the 9 cases of variceal bleed, 6 patients had rebleeding. Only one patient out 
of 41 patients of non-variceal bleed died while in the variceal side 3 out of 9 
died. 
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DISCUSSION 
 One of the major challenges of managing UGIB involves identifying 
patients who are at high risk of rebleeding and death. Identification of patients 
who are suitable for early discharge and out patient endoscopy is also important 
for effective resources use. 
 We studied, 50 patients admitted with upper gastrointestinal bleeding, in 
medical and surgical wards in our Government General Hospital. 
 We assessed the clinical severity by careful history, thorough bed side 
examination and basic blood investigations and compared it with endoscopic 
severity. 
We assessed the high risk patients by looking for several factors like age 
above 60 years, massive hemetemesis, tachycardia, shock, melena, 
haematochezia, severe anaemia at presentation, bright red blood in Ryle's 
tube aspirate, red colour in rectal examination, presence of altered 
consciousness and comorbidities like Liver, renal, cardiac disease.  
 In our study of 50 patients, 5 patients (10%) were above 60 years of age. 
40 patients (80%) were males and 10 patients (20%) were females with male : 
female ratio of 4:1. 
 Moderate blood loss was found in 13 patients (26%), severe blood loss 
in 5 patients (10%). 
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 Tachycardia with a pulse rate of more than 120 / min. was found in 8 
(16%) patients. 
 Postural hypotension was present in 11(22%) patients and resting 
hypotension, in 6(12%) patients, dizziness in 16 (32%) patients, 
unconsciousness in 4 (8%)  patients. Some of the patients had co-morbidities. 
Liver failure in 7 (14%) cases, renal failure in 4(8%), coronary artery disease in 
3(6%) cases. 
 Based on the above parameters, we divided the cases into 2 groups, high 
risk and low risk groups. Thirty six patients came under low risk group and 14 
patients came under high risk group based on logistic regression analysis. 
Patients who were above the 3rd quartile (>75%) with a clinical score above 20 
were called high risk group (HRB). 
 After the clinical risk scoring, we subjected all 50 patients for early 
endoscopy. Endoscopic results are as follows. 
 Peptic ulcer was the most common cause, accounting, for 23 (46%) 
cases. Mallory - weiss lesions were found in 6(12%) cases. Gastric erosions 
were found in 10 (20%) cases, carcinoma of stomach in 2(4%) cases, which on 
subsequent histopathological examination proved to be adenocarcinomas. 
 Esophageal varices were found in 9 (18%) cases. And of them 
associated features, indicating severity like Red colour signs were present in 5 
cases, gastric varices were found in 5 cases. Portal hypertension gastropathy in 
6 cases.  
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In the non - variceal cases, endoscopic severity of ulcers was assessed 
based on Forrest Classification. Active bleeding with spurting and oozing was 
present in 2 cases. NBVV in 2 cases, Adherent clot in 15 cases, and clean base 
or blue pigmented ulcer in 22 cases.  
 Our study accurately predicted those patients who had high risk lesions 
for massive bleeding like, spurting, oozing or NBVV in endoscopy belonged to  
the group with high risk clinical scoring (CS). 
 High risk clinical scoring correlated accurately with endoscopic high 
grade lesions. 
 Chi-square  Value  DF  P<0.001 
Pearson  25.25  4   
Several prognostic indicators in upper GI bleeding have been identified. 
The most important is the cause of bleeding. Variceal hemorrhages have much 
higher rebleeding and mortality rates than other conditions. Mortality from 
variceal hemorrhage during the initial hospitalization is at least 30%, with 
rebleeding rates of 50% to 70%37. A reduction in the mortality rates associated 
with variceal bleeding would lower the overall mortality of upper GI bleeding 
because varices account for approximately 10% of all bleeding episodes38. 
 Stigmata of recent bleeding that can be visualized at endoscopy, such as 
active arterial spurting, oozing of blood, a visible vessel, or a fresh or old blood 
clot, are important predictors of outcome in peptic ulcer bleeding. A visible 
vessel is described endoscopically as an elevated, dark red, blue, or gray 
mound that protrudes from the ulcer crater and is resistant to washing. The 
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endoscopic diagnosis of a visible vessel is actually an organizing clot plugging 
a side hole in the bleeding artery located just below the ulcer base39. The 
evolution of the endoscopic appearance of visible vessels, or sentinel clots, has 
been described as an initial large, red clot that becomes darker and smaller with 
time, eventually replaced with a white plug of fibrin and platelets that finally 
disappears40. The dark, small sentinel clot that is not oozing, also described as a 
bare visible vessel, and older stigmata in the form of a flat, black eschar or 
white clot, have lower rates of rebleeding41. Controversy regarding the 
evolution of vessel colour and the variable risks associated with the color of the 
visible vessels continues42. 
 Despite the lack of uniform endoscopic descriptions and risks for 
rebleeding depending on the type of visible vessel, the presence of a visible 
vessel in an ulcer crater at endoscopy predicts an increased risk for required 
surgical intervention and increased mortality43. The incidence of rebleeding in 
patients who have ulcers with visible vessels is up to 50%, whereas no 
rebleeding is observed in patients with no stigmata of recent bleeding44. When 
endoscopy is performed within 6 to 24 hours after admission, visible vessels 
are found in 20% to 50% of bleeding ulcers. 
 Other prognostic indicators include the following: 
 Severity of the initial bleed. Severity is assessed by the transfusion 
requirement, the presence of bright red blood in the nasogastric aspirate, or the 
presence of hypotension45. 
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 Age of the patient. Patients older than 60 years have been shown to have 
higher mortality rates than their younger counterparts, although this indicator 
may not be independent from concomitant disease3. 
 Concomitant disease. Diseases such as chronic renal failure and severe 
cardiopulmonary disease affect the ultimate outcome. 
 Onset of bleeding during hospitalization. Patients who begin to bleed 
while hospitalized have a mortality rate of 25%, whereas the rate is only 3.7% 
for patients who start to bleed before admission46. 
 In our study, in variceal bleeding, all the patients with high risk clinical 
scoring had high grade oesophageal varices and high risk clinical scoring could 
be correlated with endoscopic severity.  
 Similar study conducted by Rajesh Kashyap et al.,47 at Indira Gandhi 
Medical College Shimla, (A clinical profile of Acute Upper Gastrointestinal 
bleeding, the original article was published in JIACM 2005) concluded that the 
clinical assessment was significantly correlating with endoscopic findings (p < 
0.001).  Their study revealed that the commonest cause of UGIB was peptic 
ulcer (63%) followed by variceal bleeding (11%), Erosions (11%) MW 
syndrome (10.8%), other (6.3%). Ten percent of patients had stigmata of 
Recent hemorrhage. 
 Several population based and prospective studies, support peptic ulcer 
disease being the most common cause of UGIB, approximately in 50% of 
cases. 
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 However in a recent analysis of Clinical Outcomes Research Initiative 
(CORI) database found peptic ulcer was responsible for 20.6% of cases of 
UGIB48. The recent declining trend of PUD, in the western world could be 
attributed to widespread use of Proton Pump Inhibitors and H.Pylori 
eradication protocol and increasing use of Cox - 2 inhibitors instead of 
conventional NSAIDS.  
 In our study, 9 patients (18%) had a history of NSAIDS or aspirin in the 
previous 48 hours, which could be a precipitating factor. NSAIDS can cause 
bleeding ulcer and also increases the risk of bleeding from a pre existing ulcer. 
Study of Indhira Gandhi Medical College, showed that NSAIDS intake history 
was present in 37% of patients. 
 In our study 24 (48%) patients were alcoholics and 6 (12%) patients, had 
consumed alcohol prior to the onset of UGIB, and alcohol could be probably 
the precipitating factor among them.  
In our study, we analysed the outcomes of the patients with UGIB, and 
found that adverse outcomes like early rebleeding was present in 12(24%) 
cases. Of the 41 non-variceal cases, 6 had rebleeding and of them peptic ulcer 
was the diagnosis  in 4 cases, carcinoma stomach in 1 case and erosive mucosal 
lesions in 1 case. 
 Endoscopic instillation of 1in 10000 adrenaline to cause tamponade was 
performed and bleeding controlled in 4 patients. One patient with carcinoma of 
stomach was subsequently transferred to surgery dept. and there he underwent 
gastrectomy. One patient, admitted with massive UGIB with shock and 
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syncope, who had active bleeding during endoscopy with spurting of blood, 
subsequently died. That patient had coronary artery disease with an old 
Anterior wall myocardial infarction, a significant co-morbidity that increases 
mortality risk. 
 In variceal category, the risk of rebleeding was very high. Out of 9 
patients, 6 patients had rebleeding. Banding and Endoscopic sclerotherapy 
were performed to control bleeding. 
 In both variceal and non-variceal patients, those with high risk clinical 
score had greater chances of rebleeding, and high risk clinical scoring was 
accurate in predicting Rebleed. 
 Chi-square  Value  P<0.001 
 Pearson  23.9   
 4 (8%) patients died, variceal bleeding was the major cause of death, 
accounting for 3 (6%) cases and bleeding peptic ulcer was responsible for 1 
(2%) case. 
 In variceal bleeding, all the three patients  had  high risk clinical scoring, 
and had co-morbidities. 
 Of the three patients died of variceal bleeding, one patient had coronary 
artery disease with old Anterior wall myocardial infarction, one patient had 
renal failure, and one had both CAD and renal failure. Two patients had been 
treated in ICU. 
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 Among the 4 deaths, 3 of them were more than 60 yrs of age, died due 
to variceal bleeding and 1 patient was between 40 and 60 yrs of age, died due 
to peptic ulcer bleeding and co-morbidity (CAD). 
 In our study, those patients who died with high risk clinical scoring were 
very much in correlation with adverse outcomes, namely death. 
 Chi-square  Value  Significant 
 Pearson  11.18  P<0.001 
In a similar study conducted by Rajesh Kashyap, et al, at Indhira Gandhi 
Medical College, Shimla, adverse outcomes like rebleeding was present in 10% 
of cases, and death due to UGIB was 6.3% with variceal bleeding being  the 
most common cause of mortality and rebleeding. 
Another Indian study conducted by Rajnish Monga et al, GB Pant 
Hospital, New Delhi concluded that the predictors of rebleed, Morbidity and 
mortality, were dependent on age, presence of shock, fresh blood in Ryle's 
tube, Hb%, packed cell transfusions, co-morbid condition, stigmata of recent 
bleed on endoscopy and the underlying diagnosis. The mortality increased with  
an increase in number of co-morbid conditions. Apart from endoscopic 
stigmata of recent ulcer bleeding many independent factors predict the 
rebleeding risk. 
Similar study conducted by Vreeburg EM, et al49, Department of Gastro 
enterology, Academic Medical Centre, Amsterdam, concluded that the risk 
scoring system is a clinically useful scoring system for stratifying patients with 
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acute UGIB into high and low risk categories for mortality and predicting 
rebleeding. 
Another study conducted by Church et al50, department of 
Gastroenterology, Middle Sex Hospital, London concluded that clinical Risk 
scoring system based on Rockall score, can identify patients at high risk of 
death, but it is inadequate for the prediction of Rebleeding. 
Sanders DS et al51, department of Histopathology, Royal Hallamshire 
Hospital, Sheffield, UK, conducted a similar study and concluded that the 
clinical risk scoring system based on Rockall, was predictive of both rebleeding 
and mortality in patients with variceal hemorhage and peptic ulcer. 
Another study, conducted by Oh VJ et al52, Department of Medicine, 
Sungkyunkwan University School of Medicine, Seoul, Korea, concluded that 
the clinical risk scoring based on Rockall is useful to predict poor outcomes 
such as rebleeding and death in patients with bleeding peptic ulcer. 
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CONCLUSION 
1. Clinical risk scoring is an inexpensive tool that can identify 
patients who are at higher risk of morbidity and mortality from 
UGI bleed. 
2. There is an excellent correlation between high risk clinical 
scoring (HRB) and endoscopic severity. 
3. The clinical risk scoring can be used as a prognostic marker to 
assess Rebleeding, transfusion requirement and early mortality in 
patients with UGI bleed. 
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SUMMARY 
In our hospital, the Government General Hospital, Chennai, we started 
this study with the objectives of identifying high risk clinical features in upper 
Gastrointestinal bleeding and testing the sensitivity of high risk clinical features 
in predicting endoscopic severity and adverse outcome like Rebleed and 
Mortality. 
We studied 50 consecutive patients admitted with UGI bleed in Medical 
and Surgical wards prospectively. Clinical assessment was done by taking 
careful history, bedside examination and basic blood investigation. 
We assigned a score for each parameter with due emphasis laid over 
quantity of bleed, continued bleed, unstable hemodynamics, altered 
consciousness level and presence of co-morbidities. 
After clinical stabilisation, all the patients were subjected to early upper 
GI endoscopy. And endoscopy revealed those patients with high risk clinical 
score, had high grade ulcer bleed in the non - variceal category based on 
Forrest classification and high grade esophageal varices, in the variceal 
category. 
Endoscopy also provided an excellent correlation between high risk 
clinical scoring and early adverse outcome like Rebleed and Mortality. 
We found that clinical risk scoring was a sensitive tool in identifying 
patients who are at higher risk of morbidity and mortality from UGI bleed and 
in predicting endoscopic severity. 
PROFORMA 
 
Name:  Age: Sex : M        F 
 
Hospital No:  Occupation Address 
 
Ward:  Unit: 
 
DOA:  DOD: 
 
MODE OF PRESENTATION 
 
Hemetemesis : Yes        No      Number of Bouts 
    Amount of Blood (Total) 
    Fresh       Altered Blood  
 
Melena  :  Yes        No       Number of Episodes 
 
Bleeding : Mild  Moderate       Severe 
 
Associated Loss of consciousness :    Yes         No      
 
Blood transfusion needed :   Yes         No      
 
SYMPTOMS PRIOR TO BLEED 
 
Nausea        Vomiting   Regurgitation          Flatulence         Dysphagia 
 
Heart burn  
 
Pain : Yes         No   Site 
   Character 
   Radiation 
   Nocturnal Pain 
   Periodicity 
   Rhythmicity 
 
Weight:  Lost Stable Gained      
 
Appetite : Good Poor  
 
Bowel Habits : Normal  Diarrhoea    Constipation 
 
Recent Changes in Bowel habits : Yes        No 
 
DRUG HISTORY 
 
Aspirin         NSAIDS         Steroids        Others 
 
Ingestion within 48 Hrs of symptoms -  Yes        No 
 
PAST HISTORY 
 
History of  HT     IHD     DM     PT       Jaundice      Renal Failure      
Pulmonary disease  
 
Any other specific diseases: 
 
History of Umbilical Sepsis :  Yes         No 
 
FAMILY HISTORY 
 
Relevant          Nil Relevant  
 
PERSONAL HISTORY 
 
Smoking Habits 
 
Smoker : Yes        No   No.of Cigarettes............./day 
   No.of Years.........................  
 
Alcohol Consumption 
Alcoholic : Yes         No  Type of Beverage............................... 
   Amount.............................../day/week 
   No.of Years......................................... 
Diet :  Veg          Non-Veg  
 
GENERAL EXAMINATION 
 
Mental State:   Conscious       Dizziness          Unconscious 
 
General Appearance 
 
Nutrition : Well nourished         Moderately nourished         Malnourished  
 
Dehydration : Yes          No  Febrile / Afebrile 
 
Anaemia         Icterus       Cyanosis Clubbing 
 
Gen.Lymphadenopathy          Pedal edema 
 
Periphery  : Normal        Cold & Clammy 
 
K-F ring    Yes        No 
 
CARDIOVASCULAR SYSTEM 
 
    Supine:  mm/Hg 
Blood Pressure    Standing  mm/Hg 
    Sitting:  mm/Hg 
 
Pulse:     /min 
 
JVP:      Normal Elevated 
 
Auscultation: Heart Sounds: 
 
 Added Sounds:   
 
RESPIRATORY SYSTEM 
 
Respiratory Rate: /min 
 
Auscultation: Bilateral Air Entry:   Good         Decreased 
 Added sounds:   
ABDOMEN 
 
Tenderness : Yes          No         Site: 
 
Visible Veins : Yes          No 
 
Ascites : Yes          No 
 
Splenomegaly : Yes          No  Rectal examination 
     
Hepatomegaly : Yes          No  Ryle's tube Aspirate 
 
Mass : Yes          No 
 
CENTRAL NERVOUS SYSTEM 
 
Conscious / Oriented:   Yes          No 
 
Metabolic flap:   Yes          No 
 
Any focal neurological deficit:  Yes          No 
 
CLINICAL DIAGNOSIS 
 
 
 
CLINICAL PREDICTION:  On the basis of the evidence obtained, I predict 
that the Patient will Settle        Continue bleeding          Rebleed 
 
SUMMARY OF INVESTIGATIONS AND PROGRESS 
 
Day Hb% PCV No.of units of 
Blood transfused 
Clinical 
status 
 
 
 
 
 
    
 
INVESTIGATIONS 
 
ROUTINE 
 
Complete 
Hemogram: Hb%   Urine: 
 TC    Albumin 
 DC    Sugar 
 ESR    Deposits 
 Platelet count 
 
Blood: Urea    Urea / Creatinine= 
 Sugar 
 
Serum: Creatinine   Electrolytes 
 
SPECIFIC 
 
Blood Group / Rh typing   BT: 
PCV:    CT: 
LFT    ECG: 
    CXR: 
 
Stool : Occult Blood  - Present    Absent   
USG : Abdomen 
 
ENDOSCOPY 
 
Ulcer:            Gastric          Duodenal  Esophagus 
 
Site:     Varices: 
 
Size:     Grade: 
 
Number:     Columns: 
 
Clot        Visible Vessel        Oozing  Extent: 
 
Contents : Fresh          Altered Blood 
 
Any Growth:    Treatment: 
 
Biopsy report:    Follow up: 
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 MASTER CHART 
 
Sl. 
No. 
Age & 
Sex 
Past History H/ 
Emesis 
Melena H.chezia Hb% 
gm% 
RTA     Rec.E Pulse
per.mt 
BP 
mmHg
Cons Liver 
Failure  
Sign. 
HE Co-
mor 
NSAIDS Alco Smoki
ng 
Trans.R
EQ 
                   UGIB PUD
1.                    39/M - + 1 + - 11 2 3 88 3 3 - - - - + + -
2.                    16/M + - 3 + - 4 1 2 122 2 2 - - - - - - 4
3.                    54/M - + 2 + - 8 2 3 128 1 2 - - - + - + 2
4.                    25/M - - 1 - - 13 3 3 86 3 3 - - - - + + -
5.                    33/F - - 1 + - 10 2 - 90 3 3 - - - + - - -
6.                   62/M + - 3 + + 4 1 1 7 2 1 + + ARF,
CAD 
- + - 4
7.                    38/M - - 1 + - 10 2 3 80 3 3 - - - - - - -
8.                    46/M - - 1 - - 12 3 3 84 3 3 - - - + + + -
9.                    52/M + - 2 + - 8 1 2 126 1 2 + - - - + - 2
10. 36/F                   - - 1 + - 9 2 3 90 3 3 - - - + - - -
11. 44/F                   - - 1 + - 12 2 3 86 3 3 - - - - - - -
12. 28/M                   - - 1 + - 12 2 3 84 2 2 - - - - + + -
13. 57/M                   - - 1 + - 8 2 3 86 3 2 - - - - - - 1
14.                    26/F - - 1 - - 12 3 3 80 3 3 - - - - - - -
15. 75/M                   - - 2 + - 10 1 3 106 3 2 - - - - + + 1
16. 44/F                   - - 1 + - 11 2 3 88 3 3 - - - + - - -
17. 38/M                   + + 2 + + 8 1 2 124 2 2 - - - - + + 4
18. 48/M                   - - 1 + - 11 2 3 90 3 3 - - - - + + -
Sl. 
No. 
Age & 
Sex 
Past History H/ 
Emesis 
Melena H.chezia Hb% 
gm% 
RTA Rec.E Pulse 
per.mt 
BP 
mmHg
Cons Liver 
Failure  
Sign. 
HE Co-
mor 
NSAIDS Alco Smoki
ng 
Trans.R
EQ 
  UGIB PUD                 
19. 42/M                   - - 2 + - 8 2 2 112 2 2 - - - - - + 2
20.                    46/M + - 3 + + 4 1 1 126 1 1 - - CAD - + + 5
21. 36/F                   - - 1 + - 11 3 3 90 3 3 - - - - - - -
22.                    71/M + - 3 + + 3 1 1 132 2 1 + + ARF - + - 4
23. 74/M                   - - 1 + - 7 2 3 88 1 3 - - - - - - 2
24. 30/M                   - - 1 + - 11 3 3 90 3 3 - - - + - - -
25. 36/M                   - - 1 + - 12 2 3 86 1 3 - - - - + + -
26. 44/M                   - - 1 + - 14 2 3 92 3 3 - - - - + - -
27. 33/F                   - - 1 + - 12 2 3 90 3 3 - - - - - - -
28. 48/M                   - - 2 + - 8 1 2 106 3 2 + - - - + + 2
29.                    29/M - + 2 + - 10 2 3 108 3 3 - - - - - + 2
30.                    40/M - + 1 + - 14 3 3 86 3 3 - - - - + + -
31. 52/M                   - - 1 + - 9 2 3 90 2 3 - - - - + - 1
32. 46/M                   - - 1 + - 10 2 3 86 3 3 + - - - + + 1
33. 48/M                   + - 2 + - 8 1 2 106 3 2 - - - - + - 2
34. 36/M                   - - 1 + - 12 2 3 80 3 3 - - - - + - -
35.                    38/F - + 1 + - 12 2 3 86 3 3 - - - - - - -
36.                    42/M + + 2 + - 7 1 2 112 2 2 - - - + - + 3
37. 42/M                   - - 1 + - 12 2 3 88 3 3 - - - - + + -
Sl. 
No. 
Age & 
Sex 
Past History H/ 
Emesis 
Melena H.chezia Hb% 
gm% 
RTA Rec.E Pulse 
per.mt 
BP 
mmHg
Cons Liver 
Failure  
Sign. 
HE Co-
mor 
NSAIDS Alco Smoki
ng 
Trans.R
EQ 
  UGIB PUD                 
38. 28/M                   - - 1 + - 13 3 - 80 3 3 - - - + - + -
39.                    52/F - + 2 + - 10 1 2 126 2 2 - - - - - - 2
40.                    38/M - = 2 + - 6 1 2 116 2 2 - - CKD - - - 1
41.                    40/M - = 1 - - 12 3 - 80 3 3 - - - - - + -
42.                    58/M + = 2 + - 6 1 2 106 2 2 - - - - - - 4
43.                    46/M - + 1 + - 9 2 3 90 3 3 - - - - - + -
44.                    34/M - + 1 + - 12 2 3 86 3 3 - - - - + + -
45. 56/M                   + - 2 + - 6 1 2 116 2 2 + - - - + - 4
46. 28/F                   - - 1 + - 10 2 3 80 3 3 - - - + - - -
47.                    38/M - + 1 + - 12 2 3 82 3 3 - - - - + + -
48. 40/M                   - - 1 + - 4 2 3 78 3 3 - - - - + + -
49.                    70/M - - 3 + + 4 1 1 136 1 1 - + CAD,
ARF 
- + - 4
50. 44/F                   - - 1 + - 10 2 - 92 3 3 - - - - - - -
 
Haemetemesis   RTA (Ryle's tube Aspirate  Rectal Examination  BP 
 
1. - 500ml   1. - Bright Red    1. - Bloody   1. - Resting hypotension CAD   : Coronary artery disease 
2. - 500-1000ml   2. - Coffee brown    2. - Maroon   2. - Postural hypotension ARF   : Acute renal failure 
3. - > 1000ml   3. - Clear   3. - Melena   3. - Normal   CKD   : Chronic kidney disease 
         4. - Normal       COMOR : Comorbidities  
Consciousness    HE - Hepatic Encephalopathy         ALCO  : Alcohol 
 
1. - Unconsciousness    2. - Dizziness 
3. - Normal 
 
Sl. 
No. 
NON VARICEAL VARICEAL  Rebleed Death Remarks
          Gastric
Ulcer 
 Duodenal 
Ulcer 
Forrest Mallory
Weiss 
Erosions Others Grade Colour Gastric
Varices 
PHT. 
Gastropathy
Red 
colour 
signs 
1.               - + 3 - - - - - - - - - - -
2.              - - - - - - III White - - - - - Banding done
3.               - + 3 - - - - - - - - - - -
4.               - - 3 + - - - - - - - - - -
5.               - - 4 - + - - - - - - - - -
6.               - - - - - - IV Blue + + + + + Endoscopic
sclerotherapy 
PD done 
7.               - + 4 - - - - - - - - - - -
8.               - - 4 - + - - - - - - - - -
9.               - - - - - - III Blue + + + + - Endoscopic
ligation done 
10.               + - 4 - + - - - - - - - - -
11.               - + 3 - - - - - - - - - - -
12.               - - 4 + + - - - - - - - - -
13.              - - 4 - - Ca Stomach - - - - - + - Transferred to
surgery dept 
14.               - - 4 - + - - - - - - - - -
15.               + - 3 - - - - - - - - - - -
Sl. 
No. 
NON VARICEAL VARICEAL Rebleed Death Remarks 
 Gastric 
Ulcer 
Duodenal 
Ulcer 
Forrest Mallory 
Weiss 
Erosions Others Grade Colour Gastric 
Varices 
PHT. 
Gastropathy
Red 
colour 
signs 
   
16.               - - 4 - + - - - - - - - - -
17.               - + 4 - - - - - - - - - - -
18.               - + 4 - - - - - - - - - - -
19.               + + 3 - - - - - - - - - - -
20.               - - 1 - - - - - - - - + + Endoscopic
injection done 
21.               - + 4 - - - - - - - - - - -
22.               - - - - - - IV Blue + + + + + Peritoneal
dialysis done 
23.              - - 3 - - Ca Stomach - - - - - - - Transferred to
surgery 
24.               - - 4 - + - - - - - - - - -
25.               - + 4 - - - - - - - - - - -
26.               - - 4 + - - - - - - - - - -
27.               - - 4 - - - - - - - - - - -
28.              - - - - - - III White - - - - - Banding done
29.               - + 4 - - - III Blue + + + + - Variceal
ligation done 
30.               - + 4 - - - - - - - - - - -
Sl. 
No. 
NON VARICEAL VARICEAL Rebleed Death Remarks 
 Gastric 
Ulcer 
Duodenal 
Ulcer 
Forrest Mallory 
Weiss 
Erosions Others Grade Colour Gastric 
Varices 
PHT. 
Gastropathy
Red 
colour 
signs 
   
31.               - - - - - - II White - - - - - -
32.               - + 4 - - - - - - - - - - -
33.               - - - - - - III White + + + + - Endoscopic
sclero therapy 
34.               - - 3 + - - - - - - - - - -
35.               - + 3 - - - - - - - - - - -
36.               + + 2 - - - - - - - - + - Endoscopic
injection 
37.               - - 4 + - - - - - - - - - -
38.               - - 4 - + - - - - - - - - -
39.               + + 2 - - - - - - - - + - Endoscopic
injection done 
40.               + - 3 - - - - - - - - - - -
41.              - - 4 - - Eso erosion - - - - - - - -
42.               + - 3 - - - - - - - - + - Endoscopic
injection done 
43.               - + 4 - - - - - - - - - - -
44.               + - 3 - - - - - - - - - - -
45.               - - 1 - - - - - - - - + - Endoscopic
injection done 
Sl. 
No. 
NON VARICEAL VARICEAL Rebleed Death Remarks 
 Gastric 
Ulcer 
Duodenal 
Ulcer 
Forrest Mallory 
Weiss 
Erosions Others Grade Colour Gastric 
Varices 
PHT. 
Gastropathy
Red 
colour 
signs 
   
46.               - - 3 - + - - - - - - - - -
47.               - + 4 - - - - - - - - - - -
48.               - - - + - - - - - - - - - Endoscopic
sclerotherapy 
& PD done 
49.               + - - - - - III Blue + + + + + -
50.               - + - - - - - - - - - - - -
 
FORREST 
 
I - Active Bleeding    PD - Peritoneal Dialysis 
II - Non Bleeding Visible Vessel  ESO - Esophageal 
III - Adherent clot 
IV - Clean base (or pigment ulcer) 
Fig. 3. INCIDENCE OF VARIOUS CAUSES OF UGI BLEED IN OUR STUDY
46%
18%
20%
12%
4%
Peptic ulcer disease Variceal bleed Mucosal erosions
Mallory weiss lesions Gastric Malignancy
 MALLORY - WEISS LESION 
ENDOSCOPE VISUALISING GASTRIC 
ULCER 
GASTRIC ULCER WITH VISIBLE 
VESSEL 
GASTRIC ULCER WITH ADHERENT 
CLOT 
 
DUODENAL ULCER IN POSTERIOR 
WALL 
OESOPHAGEAL VARICEAL BLEEDING 
